<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113278</url>
  </required_header>
  <id_info>
    <org_study_id>FGL2 in brain cancer</org_study_id>
    <nct_id>NCT04113278</nct_id>
  </id_info>
  <brief_title>Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma</brief_title>
  <official_title>Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sohaila Essam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study population was selected from high grade glioma pateints attending the Department of
      Clinical Oncology, Assiut University hospital during the period from December 2018 to
      September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma is the most common malignant primary brain tumor in adults, and despite
      aggressive treatment, it is incurable Patient prognosis differs considerably within the
      different World Health Organization (WHO) grades, poorest prognosis for patients with the
      grade IV tumour- the glioblastoma multiform (GBM).

      Fibrinogen-like protein 2 (FGL2),regulates both innate and adaptive immunity. FGL2 is a 439
      amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen.

      Secreted FGL2 (sFGL2) is the key regulator in immunosuppression may play important role in
      malignant transformation of low to high by inhibiting the proliferation of T cell Study the
      role of fibrinogen-like protein2 on Immunosuppression and progression ，free survival and
      overall survival in high grade glioma
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rple of FGL2in high grade glioma as aprognostic factor</measure>
    <time_frame>baseline</time_frame>
    <description>Correlation between FLG2 expression and progression free survival and overall survival</description>
  </primary_outcome>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Brain Tumor Adult</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>FGL2 immunohisyochemistry</intervention_name>
    <description>Correlation between FLG2 expression and progression free survival and overall surviv</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population was selected from high grade glioma pateints attending the Department
        of Clinical Oncology, Assiut University hospital during the period from December 2018 to
        September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pateints&gt;18 years old

          -  Pathologically proven high grade glioma

          -  Total or subtotal resection of the tumor

          -  Patients received concurrent radiation therapy with temozolomide followed by adjuvant
             temozolamide for 6 months

        Exclusion Criteria:

          -  Pregnancy

          -  Breast feeding

          -  Other comorbidity

          -  Previous malignancy or radiation therapy or chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>samir shehata, professor</last_name>
    <phone>01222302375</phone>
    <email>Samir-eid@Hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohammed alaa, professor</last_name>
    <phone>01005085973</phone>
    <email>m.alaa200@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107.</citation>
    <PMID>29947810</PMID>
  </reference>
  <reference>
    <citation>Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation. Nat Commun. 2019 Jan 25;10(1):448. doi: 10.1038/s41467-018-08271-x. Erratum in: Nat Commun. 2019 Feb 15;10(1):862.</citation>
    <PMID>30683885</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>sohaila Essam</investigator_full_name>
    <investigator_title>Role of fibrinogen like protein 2 as aprognostic factor in high grade glioma</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

